Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs.
biologics
chronic kidney disease
inflammation
rheumatoid arthritis
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
11
09
2021
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
We investigated the incidence of chronic kidney disease (CKD) progression and its factors relevant to patients with stable rheumatoid arthritis (RA). We enrolled consecutive patients with RA who had initiated treatment with a biologic disease-modifying anti-rheumatic drug (bDMARD) at our institution and continued the same drug for >5 years between 2001 and 2016. Patients with CKD at bDMARD initiation were excluded. C-reactive protein (CRP) level, Clinical Disease Activity Index (CDAI) score and estimated glomerular filtration rate were measured every 6 months. We included 423 patients, with 196 on tumour necrosis factor inhibitors, 190 on tocilizumab and 37 on abatacept. Among these patients, 34 (8.0%) progressed to CKD within 5 years. The mean CRP level and CDAI score over 5 years were significantly lower in patients without CKD progression than in those with CKD progression ( Controlling inflammation contributes to the inhibition of CKD progression in RA patients.
Sections du résumé
Background
UNASSIGNED
We investigated the incidence of chronic kidney disease (CKD) progression and its factors relevant to patients with stable rheumatoid arthritis (RA).
Methods
UNASSIGNED
We enrolled consecutive patients with RA who had initiated treatment with a biologic disease-modifying anti-rheumatic drug (bDMARD) at our institution and continued the same drug for >5 years between 2001 and 2016. Patients with CKD at bDMARD initiation were excluded. C-reactive protein (CRP) level, Clinical Disease Activity Index (CDAI) score and estimated glomerular filtration rate were measured every 6 months.
Results
UNASSIGNED
We included 423 patients, with 196 on tumour necrosis factor inhibitors, 190 on tocilizumab and 37 on abatacept. Among these patients, 34 (8.0%) progressed to CKD within 5 years. The mean CRP level and CDAI score over 5 years were significantly lower in patients without CKD progression than in those with CKD progression (
Conclusions
UNASSIGNED
Controlling inflammation contributes to the inhibition of CKD progression in RA patients.
Identifiants
pubmed: 35756739
doi: 10.1093/ckj/sfac036
pii: sfac036
pmc: PMC9217658
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1373-1378Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
Am J Kidney Dis. 2014 Feb;63(2):206-13
pubmed: 24100126
Kidney Int. 2014 Jan;85(1):49-61
pubmed: 24284513
Clin Exp Nephrol. 2007 Jun;11(2):156-163
pubmed: 17593516
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Nephrol Dial Transplant. 2015 Apr;30(4):564-74
pubmed: 25011387
Kidney Int. 2005 Jul;68(1):237-45
pubmed: 15954913
Ann Rheum Dis. 2010 Apr;69(4):631-7
pubmed: 20215140
J Biol Chem. 2005 Apr 1;280(13):12239-45
pubmed: 15661740
Ann Rheum Dis. 2020 May;79(5):671-674
pubmed: 31996365
Cleve Clin J Med. 2002;69 Suppl 1:SI53-8
pubmed: 12086295
Kidney Int Suppl (2011). 2013 Dec;3(4):368-371
pubmed: 25019021
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Ann Rheum Dis. 2010 Jun;69(6):964-75
pubmed: 20444750
Nephrol Dial Transplant. 2017 Dec 01;32(12):2035-2042
pubmed: 27638912
Nephron Clin Pract. 2004;96(4):c107-14
pubmed: 15122064
J Am Soc Nephrol. 2008 Jun;19(6):1106-15
pubmed: 18337485
PLoS One. 2016 Aug 18;11(8):e0160225
pubmed: 27537204
Am J Med. 2007 Mar;120(3):280.e1-7
pubmed: 17349452
CEN Case Rep. 2012 May;1(1):7-11
pubmed: 28509146
Kidney Int. 2018 May;93(5):1207-1216
pubmed: 29409725
Rheumatology (Oxford). 2021 Nov 3;60(11):5247-5256
pubmed: 33682890
NDT Plus. 2008 Dec;1(6):423-426
pubmed: 28656995
Clin Rheumatol. 2007 Dec;26(12):2089-2095
pubmed: 17492249
Clin Nephrol. 1998 Sep;50(3):154-60
pubmed: 9776418
Ann Rheum Dis. 2014 Mar;73(3):492-509
pubmed: 24161836
Hypertens Res. 2008 Mar;31(3):433-41
pubmed: 18497462
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Am J Kidney Dis. 2003 Jun;41(6):1212-8
pubmed: 12776273
J Clin Invest. 1999 Oct;104(8):1007-9
pubmed: 10525035
Nephron. 1997;77(2):176-85
pubmed: 9346384